ExodusPoint Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

ExodusPoint Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.01M	Sell	161,700 -664,299	-80%	-$8.92M	0.02%	781
2025 Q4	$10.4M	Buy	825,999 +83,186	+11%	+$952K	0.08%	251
2025 Q3	$7.44M	Buy	742,813 +211,032	+40%	+$1.89M	0.08%	282
2025 Q2	$4.3M	Buy	+531,781	New	+$4.01M	0.04%	468
2025 Q1	–	Sell	-108,267	Closed	-$857K	–	1429
2024 Q4	$857K	Buy	+108,267	New	+$908K	0.01%	993
2024 Q3	–	Sell	-111,969	Closed	-$711K	–	1593
2024 Q2	$711K	Buy	+111,969	New	+$711K	﹤0.01%	1126
2023 Q4	–	Sell	-47,484	Closed	-$200K	–	1430
2023 Q3	$200K	Buy	+47,484	New	+$177K	﹤0.01%	1525
2022 Q1	–	Sell	-23,292	Closed	-$112K	–	2160
2021 Q4	$112K	Buy	+23,292	New	+$116K	﹤0.01%	1940
2021 Q3	–	Sell	-42,032	Closed	-$215K	–	2069
2021 Q2	$215K	Buy	+42,032	New	+$239K	﹤0.01%	1942

Other funds holding AMRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

ExodusPoint Capital Management's AMRX Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Amneal Pharmaceuticals (AMRX) stake by 80% in Q1 2026, selling an estimated $8.92M and leaving 161,700 shares worth $2.01M. The position accounts for 0.02% of the portfolio, ranked #781.

ExodusPoint Capital Management first reported a position in AMRX in Q2 2021 and has held it in 9 quarters since. The position peaked at $10.4M in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

ExodusPoint Capital Management held 161,700 shares of Amneal Pharmaceuticals worth $2.01M as of Q1 2026.
ExodusPoint Capital Management sold 664,299 Amneal Pharmaceuticals shares in Q1 2026, an estimated $8.92M.
Amneal Pharmaceuticals made up 0.02% of ExodusPoint Capital Management's portfolio in Q1 2026, its #781 holding.
ExodusPoint Capital Management first reported a position in Amneal Pharmaceuticals in Q2 2021 and has held it in 9 quarters since.
ExodusPoint Capital Management's Amneal Pharmaceuticals position peaked at $10.4M in Q4 2025.
315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.